KPIs & Operating Metrics(New)
Growth Metrics

Abbott Laboratories (ABT) Liabilities and Shareholders Equity (2016 - 2025)

Abbott Laboratories' Liabilities and Shareholders Equity history spans 17 years, with the latest figure at $84.2 billion for Q3 2025.

  • For Q3 2025, Liabilities and Shareholders Equity rose 13.21% year-over-year to $84.2 billion; the TTM value through Dec 2025 reached $165.6 billion, down 45.02%, while the annual FY2024 figure was $81.4 billion, 11.2% up from the prior year.
  • Liabilities and Shareholders Equity for Q3 2025 was $84.2 billion at Abbott Laboratories, up from $81.4 billion in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $84.2 billion in Q3 2025 and bottomed at $7.3 billion in Q4 2021.
  • The 5-year median for Liabilities and Shareholders Equity is $73.3 billion (2021), against an average of $67.5 billion.
  • The largest annual shift saw Liabilities and Shareholders Equity tumbled 65.35% in 2021 before it soared 816.89% in 2023.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $7.3 billion in 2021, then grew by 9.97% to $8.0 billion in 2022, then skyrocketed by 816.89% to $73.2 billion in 2023, then grew by 11.2% to $81.4 billion in 2024, then rose by 3.4% to $84.2 billion in 2025.
  • Per Business Quant, the three most recent readings for ABT's Liabilities and Shareholders Equity are $84.2 billion (Q3 2025), $81.4 billion (Q1 2025), and $81.4 billion (Q4 2024).